Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of SYNT001 in Healthy Volunteers
NCT03643627Phase 1Completed
- Sponsor
- Syntimmune
- Start
- Aug 2016
- Primary completion
- Apr 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orilanolimab in warm autoimmune hemolytic anemia (wAIHA), pemphigus vulgaris (PV) and pemphigus foliaceus (PF) (5 arms), sponsored by Syntimmune. Primary endpoint: Assessment of safety data (counts and percentages of adverse events). Started Aug 2016; status: completed.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT03643627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643627.